Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy.

Antigens, CD19 Cell- and Tissue-Based Therapy Humans Immunotherapy, Adoptive Lymphoma, Large B-Cell, Diffuse / therapy Receptors, Chimeric Antigen
CAR-T cell eligibility CAR-T cells Diffuse large B-cell lymphoma relapse-refractory disease

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 5 12 2020
medline: 1 5 2021
entrez: 4 12 2020
Statut: ppublish

Résumé

Anti-CD19 chimeric antigen receptor (CAR) T cells represent the first approved third-line therapy associated with long-term remissions in patients with refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). Eligibility criteria to identify patients who can successfully receive CAR-T are still debated. For this reason, the aim of this study was to identify factors influencing eligibility and define a realistic patient estimate. Of 1100 DLBCL patients, 137 were included. Based on the Juliet trial inclusion criteria, only 64 patients (46.7%) would be eligible. Median overall survival (OS) was 8.04 months in eligible

Identifiants

DOI: 10.1080/10428194.2020.1849676 PMID: 33274677
pubmed: 33274677
doi: 10.1080/10428194.2020.1849676
doi:

Substances chimiques

Antigens, CD19 0
Receptors, Chimeric Antigen 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

828-836

Auteurs

Alice Di Rocco (A)

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
ORCID: 0000-0003-0985-9623

Antonio Cuneo (A)

Department of Hematology, S. Anna Hospital, University of Ferrara, Ferrara, Italy.

Arianna Di Rocco (A)

Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.

Francesco Merli (F)

Hematology, AUSLL/IRCCS Santa Maria Nuova Hospital, Reggio Emilia, Italy.

Giulia De Luca (G)

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

Luigi Petrucci (L)

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

Michela Ansuinelli (M)

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

Domenico Penna (D)

Hematology, AUSLL/IRCCS Santa Maria Nuova Hospital, Reggio Emilia, Italy.
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Francesco Rotondo (F)

Department of Hematology, S. Anna Hospital, University of Ferrara, Ferrara, Italy.

Gian Matteo Rigolin (GM)

Department of Hematology, S. Anna Hospital, University of Ferrara, Ferrara, Italy.

Mariateresa Giaimo (M)

Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.

Francesca Re (F)

Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.

Alessio Farcomeni (A)

Department of Economics and Finance, University of Rome "Tor Vergata", Rome, Italy.
ORCID: 0000-0002-7104-5826

Maurizio Martelli (M)

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

Robin Foà (R)

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes B › Antigènes CD19 › Relapsed/refractory diffuse large B-cell...
Recherchemedicale.com › Thérapeutique › Biothérapie › Thérapie cellulaire et tissulaire › Relapsed/refractory diffuse large B-cell...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Relapsed/refractory diffuse large B-cell...
Recherchemedicale.com › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Immunothérapie adoptive › Relapsed/refractory diffuse large B-cell...
Recherchemedicale.com › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Lymphome B diffus à grandes cellules › Relapsed/refractory diffuse large B-cell...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs chimériques pour l'antigène › Relapsed/refractory diffuse large B-cell...